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Abstract: Kafirin microparticles have potential as colon-targeted delivery systems because of their
ability to protect encapsulated material from digestive processes of the upper gastrointestinal tract
(GIT). The aim was to optimize prednisolone loading into kafirin microparticles, and investigate
their potential as an oral delivery system. Response surface methodology (RSM) was used to
predict the optimal formulation of prednisolone loaded microparticles. Prednisolone release from the
microparticles was measured in simulated conditions of the GIT. The RSM models were inadequate for
predicting the relationship between starting quantities of kafirin and prednisolone, and prednisolone
loading into microparticles. Compared to prednisolone released in the simulated gastric and small
intestinal conditions, no additional drug release was observed in simulated colonic conditions.
Hence, more insight into factors affecting drug loading into kafirin microparticles is required to
improve the robustness of the RSM model. This present method of formulating prednisolone-loaded
kafirin microparticles is unlikely to offer clinical benefits over commercially available dosage
forms. Nevertheless, the overall amount of prednisolone released from the kafirin microparticles in
conditions simulating the human GIT demonstrates their ability to prevent the release of entrapped
core material. Further work developing the formulation methods may result in a delivery system
that targets the lower GIT.
Keywords: kafirin; distiller’s dried grains with solubles; microparticles; response surface
methodology; simulated gastrointestinal conditions; colonic delivery
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1. Introduction
Kafirin microparticles have been investigated for their potential as an oral delivery system.
Kafirins are storage proteins of the sorghum grain, and their characteristic hydrophobic and poorly
digestible nature [1–3] has been identified as a potential delivery system that can target or delay
the release of medications. For instance, approximately 20–25% of the prednisolone loaded into
microparticles made using kafirin extracted from whole grain sorghum, was released over seven
hours in simulated gastric and small intestinal conditions. These results suggest the kafirin
microparticles have potential as a colon-targeted delivery system since they can protect the majority
of the encapsulated material from being released in the upper GIT [4]. One of the reasons for the
low digestibility of the kafirin protein is thought to be due to its formation of multiple disulfide
bond crosslinks, which protects against hydrolysis by digestive enzymes [5–7]. Previous work on
polysaccharides and pro-drugs have shown that delivery systems targeting the microbes of the
colon holds promise as a reliable colon-targeted drug delivery system [8–13]. Given the presence of
the colonic (anaerobic) bacterial microbiota, and the resulting low redox, it is hypothesized that
these disulfide bonds may be reduced (cleaved) upon entry to the colon, thereby releasing the
encapsulated drug.
To be commercially viable as a drug delivery system, wastage of material must be minimized
during the process of formulating these microparticles. As the factors involved in influencing
prednisolone loading into the kafirin microparticles are not yet well understood, it is difficult to
manipulate and optimize the amount of drug (core material) that is loaded. Response surface
methodology (RSM) is a well-established statistical modeling method that has previously been used
in the pharmaceutical industry to model and optimize formulations of drug delivery systems. Some
examples include tamsulosin pellets [14], indomethacin pellets [15], zein microcapsules loaded with
flax oil [16], chitosan microparticles loaded with felodipine [17], Eudragit®microparticles loaded with
captopril [18], controlled release mesalazine tablets [19], and controlled release atenolol tablets [20] for
oral delivery. RSM has also been used to model the formulation of diclofenac and curcumin gels for
topical delivery [21]. RSM involves identifying factors that contribute to the desired outcomes. The
interactions between the factors that affect the outcome are mapped so that optimum conditions can
be established. RSM uses statistical modeling with regression equations to describe the relationship
between these factors and the outcomes. From these models, an optimized combination of factors may
be determined to generate a desired outcome. For instance, in designing formulations for drug delivery
systems, the aim would be to minimize the amount of material used or wasted, whilst maximizing the
amount of drug loaded [22].
Based on preliminary work, three variables appear to have an effect on the amount of prednisolone
loaded into the microparticles: the starting quantities of kafirin; the starting quantities of prednisolone;
and the inclusion of sodium chloride (NaCl) [23]. In this work, RSM will be used to build a statistical
model that can be used to predict the combination of independent variables which are required to
achieve any level of prednisolone loading and loading efficiency, i.e., the dependent variables. This
will allow optimization of the formulation to produce kafirin microparticles loaded with prednisolone.
The kafirin formulation with the optimal prednisolone loading will then be tested for their potential as
an oral delivery system in conditions simulating the stomach and small intestine, and in the colon.
The particle size and thermodynamic stability of the prednisolone-loaded microparticles will also be
measured over a period of six months.
2. Materials and Methods
2.1. Kafirin Source and Extraction, and Formulating Kafirin Microparticles
Distiller’s dried grains (DDG) kafirin was extracted from the protein-rich waste stream following
biofuel production (i.e., DDGS) with red grain sorghum at a sorghum refinery (Dalby Bio-refinery,
Dalby, Australia) [23]. Microparticles were formulated according to the method reported for
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loading prednisolone into kafirin microparticles [23], which was adapted from formulating zein
microparticles [24]. A solution of NaCl was used to form the prednisolone-loaded microparticles
by inducing phase separation in a prednisolone-ethanol solution. The microparticles were
freeze-dried overnight before being analyzed for prednisolone loading, and loading efficiency into the
microparticles using HPLC [23,24]. Reagents were of analytical and HPLC grades.
2.2. Response Surface Methodology
The independent variables, kafirin protein (X1) and the amount of prednisolone (X2), were
investigated for their effects on the dependent variables, prednisolone loading (Y1) and loading
efficiency (Y2) (Table 1). Drug loading was not significantly different across the range of NaCl
concentrations investigated (0.01–5 M) [23], so the amount of NaCl used in the formulation was kept
constant at 8 mL of 0.1 M.
Table 1. Variables in the central composite design.
Real Independent
Variables
Coded Independent Variable Levels
Corner Points Centre Point Star Points
–1.414 –1.0 0 +1.0 +1.414
X1 = kafirin (mg) 37.87 100 250 400 462.13
X2 = prednisolone (mg) 48.25 100 225 350 401.75
Real dependent variables -
Y1 = prednisolone loading (%)
amount of prednisolone (mg) in microparticles
amount of microparticles (mg) ×100
Y2 = loading efficiency (%)
amount of prednisolone (mg) in microparticles
amount of prednisolone (mg) initially added ×100
A two-factor, three-level central composite design was used, with five replicates at the center
point, generating a total of 13 runs. The levels of the independent variables investigated were
5–20 mg/mL kafirin (i.e., 100–400 mg), and 5–17.5 mg/mL of prednisolone (i.e., 100–350 mg), with each
experimental formulation made in triplicate. These ranges were determined based on the preliminary
work on loading prednisolone into kafirin microparticles [23], in conjunction with the work on zein
microparticles loaded with prednisolone [25]. The variable effects were modelled using the equation
for two process variables [15,16,26–28]:
y = β0 + β1X1 + β2X2 + β11X12 + β22X22 + β12X1X2 + ε (1)
where y is the dependent variable (or response), β0 is the intercept, β1 and β2 are the regression
coefficients of the linear order effect, β11 and β22 are the quadratic order effect, β12 is the linear
interaction order effect, and ε is the experimental error term [16,19,26,28]. Design-Expert 8.0.6
(Stat-Ease, Inc., MN, USA) was used to model the data. The level of significance was set at p < 0.05, and
r2 and lack of fit were used to gauge the adequacy of the model [29]. Response surface plots and contour
plots were generated using the polynomial equations. The surface plots allowed the relationship
between the independent variables and responses to be visualized. These were used to predict the
levels of independent variables required to produce a defined response. The contour plots provided a
continuous predictive tool to predict the response given any combination of independent variables.
2.3. Optimization Data Analysis and Validation of Optimization Model
The combination of independent variables required to produce an optimal response based on
a set of imposed constraints can be calculated with the model generated using RSM. Prednisolone
loading is a measure of the proportion of prednisolone in the microparticles, so a higher value is
more desirable. Similarly, a higher loading efficiency is more desirable as it is a measure of the
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amount of prednisolone loaded, as a percentage of the amount of prednisolone initially added. Thus,
the goals of the optimization prediction were to maximize both prednisolone loading and loading
efficiency. During the calculation of the optimization statistics, equal importance was assigned to
each variable and both responses, as it was equally important for both prednisolone loading and
loading efficiency to be maximized, whilst minimal or reasonable quantities of kafirin and prednisolone
were used. Design-Expert 8.0.6 (Stat-Ease Inc, Minneapolis, MN, USA) was used to plot the optimal
combination of variables required to generate the desired response of maximized drug loading and
loading efficiency from the RSM models. To obtain an acceptable prediction of the optimal combination
of kafirin and prednisolone, the minimal level of the responses used was 10% for drug loading and 15%
for loading efficiency. The relationship between the variables and both responses were mapped on a
single contour plot, essentially producing an overlay of the contour plots for prednisolone loading and
loading efficiency, providing a visual representation of the optimized outcome. The predicted optimal
and non-optimal combinations were reformulated in triplicate to verify the model. A ′non-optimal′
combination of 200 mg kafirin and 200 mg prednisolone was arbitrarily selected as it was not used
originally in the development of the model, and because it is within the boundaries of the range of
independent variables used in this RSM study (i.e., 100–350 mg prednisolone, and 100–400 mg kafirin).
The error between the values of the responses predicted by the RSM model, and the experimentally
determined values of the responses for the ′optimal′ and ′non-optimal′ formulations were calculated
as follows:
Predicted error (%) =
Observed value− Predicted value
Predicted value
× 100 (2)
2.4. Scanning Electron Microscopy
The freeze-dried kafirin microparticle samples were mounted onto carbon tabs and coated with
10 nm of platinum using a sputter coater (Baltec MED 020, Leica Microsystems, Wetzlar, Germany).
The samples were then viewed at 5 kV and a working distance of 8 mm using a field emission scanning
electron microscope JSM 6300F (JEOL, Tokyo, Japan) [4,23,25].
2.5. Particle Size Distribution
Freeze-dried microparticles (50 mg) dispersed in 50 mL of 40% (v/v) ethanol were analyzed by
laser diffraction using a Mastersizer 2000E (Malvern Instruments, Malvern, UK) and a small volume
sample dispersion unit (Malvern Instruments, Malvern, UK). The refractive index used for kafirin was
1.45 and 1.33 for 40% (v/v) ethanol. The obscuration range was between 10% and 20%, with a residual
of less than 1%. Particle size was measured in duplicate for each sample [25].
2.6. Stability Testing
Stability studies were conducted on the prednisolone loaded kafirin microparticles at 4.5 ◦C
and 25◦C/60% relative humidity, and under accelerated conditions at 40◦C/60% relative humidity
for 6, 12 and 24 weeks [30]. Aliquots (10 mg) of the optimal microparticle formulation identified
using RSM were weighed into low protein binding centrifuge tubes, capped, and then wrapped in foil
(three replicates for each storage condition and temperature). Microparticles formulated without kafirin
were used as the drug control. At each time-point, three aliquots of each microparticle formulation
were removed and the amount of drug leakage as measured by the amount of prednisolone washed
out was quantified using HPLC [4,23,25].
2.7. In vitro Drug Release
2.7.1. Simulated Gastric and Small Intestinal Conditions
Prednisolone release from the optimal microparticle formulation identified using RSM were
measured in simulated gastric and small intestinal conditions. The United States Pharmacopeia (USP)
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dissolution Apparatus 2 fitted with a small volume vessel (100 mL) was used [31]. The medium was
made according to the British Pharmacopoeia (BP) [32], for a test using increasing pH to simulate the
stomach and small intestine for 7 h. Drug release was also measured using the same medium in the
presence of enzymes, where pepsin (0.32 g, 0.7 FIP-U/mg; AppliChem, Darmstadt, Germany) was
added to the medium at 0 h, and pancreatin (1 g, 23664 FIP-U/g; AppliChem, Darmstadt, Germany)
was added at 1 h. In a separate test, prednisolone release from the kafirin microparticles was also
measured in simulated small intestinal conditions with pancreatin in the presence of bile salts for
4 h. Simulated intestinal fluid with pancreatin was made according to the British Pharmacopoeia [32],
then 8 mg/mL of bile salts (Chem-Supply Pty Ltd, Gillman, Australia), equivalent to c. 15 mM,
was added as it is purportedly similar to the bile salt concentration present in human intestinal
fluids in a fed state [33–35]. Drug release from approximately 30 mg of microparticles containing
5 mg of prednisolone was compared with that of a commercially available 5 mg prednisolone tablet
(PanafcorteloneTM, Aspen Pharmacare, St Leonards, Australia). At regular time intervals, samples
were retrieved and analyzed using HPLC [4,23,25].
2.7.2. Simulated Colonic Conditions
An In vitro fermentation method using pig feces was used to simulate the conditions of the
colon [36], as a pig model of digestion is appropriate for mimicking human colonic function [37].
Furthermore, it is convenient to use porcine fecal inoculum due to consistency between the pigs, and
also because the diet of the pigs can be controlled. This means that measures can be taken to ensure
that the microbes have not been pre-exposed to the substrates tested, which would otherwise allow
the microbial enzymes to adapt [37].
Fecal Inoculum
Feces were collected per-rectum from five pigs that were offered a ′control diet′, which was
based on highly digestible corn starch and fishmeal, for at least 10 days. The feces were placed into a
pre-warmed vacuum flask that had been flushed with CO2 for transfer back to the laboratory. The feces
were combined and diluted in a ratio of 1:5 using sterile saline (0.9% w/v NaCl) pre-warmed to 39 ◦C.
This mixture was mixed using a hand-held blender for 1 min, strained through four layers of muslin
cloth, then stirred constantly and flushed with a continuous stream of CO2, before being added (5 mL)
to the substrates and medium. For the autoclaved fecal inoculum, a sample of the blended and strained
mixture was autoclaved at 121 ◦C for 15 min, before 5 mL was added to the substrates and medium as
a control.
Substrates and Medium
The medium was prepared using an In vitro batch culture method consisting of the basal
solution (68 mL), reducing agent (1 mL), bicarbonate solution (1 mL), and vitamin-phosphate solution
(4 mL) [36]. Pre-weighed glucose was added to provide a source of energy (carbohydrate) for
the microbes.
Table 2 provides a summary of the substrates used for fermentation. Three replicates of kafirin
microparticles loaded with prednisolone were analyzed (Table 2; substrates 1–3). Six replicates of
each substrate (c. 30 mg) were then weighed into serum bottles for fermentation. One blank and four
controls were used, of which three contained no prednisolone (Table 2; substrates 4–6). Commercially
available 5 mg prednisolone tablets were included as positive controls, with substrate 8 (the autoclaved
fecal inoculum) used to assess any impact the fecal matter had on prednisolone detection.
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Table 2. Classification and description of the substrates used for fermentation in the simulated
conditions of the colon.
Substrate Number Substrate Classification Description
1 Sample: replicate 1 Kafirin microparticles loaded with prednisolone equivalent to5 mg of prednisolone + fecal inoculum + 0.5 g glucose
2 Sample: replicate 2 Kafirin microparticles loaded with prednisolone equivalent to5 mg of prednisolone + fecal inoculum + 0.5 g glucose
3 Sample: replicate 3 Kafirin microparticles loaded with prednisolone equivalent to5 mg of prednisolone + fecal inoculum + 0.5 g glucose
4 Blank Medium + fecal inoculum
5 Control 1: for glucose Fecal inoculum + 0.5 g glucose
6 Control 2: for microparticles Kafirin microparticles (no prednisolone) + fecal inoculum
7 Control 3: for microparticles Commercially available 5 mg prednisolone tablets +fecal inoculum + 0.5 g glucose
8 Control 4: for microparticles andfecal inoculum
Commercially available 5 mg prednisolone tablets +
autoclaved fecal inoculum
Three replicates from each substrate were used for gas measurements. These bottles were
randomized on a single tray and fermented at 39◦C. Samples (2 mL) were removed from the remaining
three replicates at regular time intervals, to quantify the amount of prednisolone present at –16, 0,
2, 4, 8, 12, 19 and 24 h. Each bottle was gently swirled to achieve a homogenous mixture before the
samples were removed. The –16 h samples were taken one hour after the medium had been added to
all the bottles at –17 h, while the 0 h samples were when the fecal inoculum was added to the bottles.
The 2 mL samples were centrifuged at 15,000 rpm at 4 ◦C for 5 min. The resulting supernatant was
filtered through 0.45 µm Durapore filter paper before being analyzed by HPLC [4,23,25].
2.8. Statistical Analysis
One-way ANOVA with a Bonferroni post-hoc test were used to compare the percentage of
prednisolone released after one hour of the dissolution study from the kafirin microparticles in the
presence and absence of enzymes. GraphPad Prism 5.04 (GraphPad Software, San Diego, CA, USA)
was used with the level of significance set as p < 0.05.
3. Results
3.1. Response Surface Methdology
At the various concentrations of kafirin and prednisolone used, prednisolone loading ranged
from 2.13% to 15.57%, while loading efficiency ranged from 5.26% to 36.92%. The model generated
using the regression coefficients relating the dependent variables to the independent variables in coded
values were:
Prednisolone loading (Y1) = +7.25 − 0.21X1 + 3.37X2 (3)
Loading efficiency (Y2) = +14.67 + 5.98X1 − 1.38 X2 + 5.99X22 (4)
This predicts that a higher starting quantity of prednisolone will produce higher drug loading.
Similarly, high loading efficiency may be achieved with larger quantities of kafirin. Prednisolone
loading (%) significantly increased with increasing quantities of prednisolone, while there was
a negative trend with kafirin quantity (Figure 1, Equation (3)); though this was not statistically
significant (Table 3). Similarly, the model predicts that loading efficiency (%) significantly increases
with increasing kafirin quantities (mg), while the effect of prednisolone quantities (mg) on loading
efficiency demonstrated a strong trend at the quadratic level (p = 0.0522) (Figure 2, Equation (4) and
Table 3).
Pharmaceutics 2017, 9, 17 7 of 16
Pharmaceutics 2017, 9, 17  7 of 16 
 
 
Figure 1. Contour plot showing the effects of kafirin and prednisolone quantities (mg) on (Y1) 
prednisolone loading (%). The numbers in the small squares refer to the response value.  
 
Figure 2. Contour plot showing the effects of kafirin and prednisolone quantities (mg) on (Y2) loading 
efficiency (%). The numbers in the small squares refer to the response value.  
Table 3. Contributions of independent factors to the mathematical model expressed as coefficients 
with p-values. 
Response Intercept X1 X2 X22 
Y1  7.25 –0.21 3.37 - 
p-value  - 0.8301 0.0055 - 
Y2 14.67 5.98 –1.38 5.99 
p-value  - 0.0417 0.5964 0.0522 
NB: Response Y1 = prednisolone loading (%), Y2 = loading efficiency (%). The intercept X1 = linear 
regression coefficient for the coded quantities of kafirin, X2 = linear regression coefficient for the coded 
quantities of prednisolone, while X22 = the quadratic regression coefficient for the coded quantities of 
prednisolone.  
Figure 1. Contour plot showing the effects of kafirin and prednisolone quantities (mg) on (Y1)
prednisolone loading (%). The numbers in the small squares refer to the response value.
Pharmaceutics 2017, 9, 17  7 of 16 
 
 
Figure 1. Contour plot sho ing the effects of kafirin and prednisolone quantities ( g) on (Y ) 
prednisolone loading (%). The numbers in the small squares refer to the response value.  
 
Figure 2. Contour plot showing the effects of kafirin and prednisolone quantities (mg) on (Y2) loading 
efficiency (%). The numbers in the small squares refer to the response value.  
Table 3. Contributions of independent factors to the mathematical model expressed as coefficients 
with p-values. 
Response Intercept X1 X2 X22 
Y1  7.25 –0.21 3.37 - 
p-value  - 0.8301 0.0055 - 
Y2 14.67 5.98 –1.38 5.99 
p-value  - 0.0417 0.5964 0.0522 
NB: Response Y1 = prednisolone loading (%), Y2 = loading efficiency (%). The intercept X1 = linear 
regression coefficient for the coded quantities of kafirin, X2 = linear regression coefficient for the coded 
quantities of prednisolone, while X22 = the quadratic regression coefficient for the coded quantities of 
prednisolone.  
Figure 2. Contour plot showing the effects of kafirin and prednisolone quantities (mg) on (Y2) loading
efficiency (%). The nu bers in the s all squares refer to the response value.
Table 3. Contributions of independent factors to the mathematical model expressed as coefficients
with p-values.
Response Intercept X1 X2 X22
Y1 7.25 –0.21 3.37 -
p-value - 0.8301 0.0055 -
Y2 14.67 5.98 –1.38 5.99
p-value - 0.0417 0.5964 0.0522
NB: Response Y1 = prednisolone loading (%), Y2 = loading efficiency (%). The intercept X1 = linear regression
coefficient for the coded quantities of kafirin, X2 = linear regression co fficient for the oded quantities of
prednisolone, while X22 = the quadratic regression coefficient for the coded quantities of prednisolone.
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Overall, the model (linear) for prednisolone loading (Equation (3)) was significant (p = 0.0174),
with an insignificant lack of fit (p = 0.0882) supporting the adequacy of the model. However, the r2
of the model was only 55.54%, which indicates that the model is not well correlated with the data
gathered in our experiments, reducing its adequacy for predictive purposes. The loading efficiency
model (quadratic) shows a strong trend towards significance (p = 0.0573). The lack of fit for the
quadratic loading efficiency model is also significant (p = 0.0502) and has a r2 of 54.85%. Ideally, an
adequate model would be statistically significant, have an insignificant lack of fit, and r2 of at least
80% [29]. Hence, the RSM models generated in this study lack adequacy for modeling purposes.
Nevertheless, these RSM models are still useful in identifying trends between the independent and
dependent variables.
3.2. Optimization Data Analysis and Validation of Optimization Model and Thermodynamic Stability
The predicted optimal combination can be visualized on the overlay of the prednisolone loading
and loading efficiency contour plots (Figure 3). The yellow panel on the top right-hand corner of
the overlay plot shows the optimal zone where the constraints are met according to this RSM model.
As such, the RSM model predicted that the optimal combination of kafirin and prednisolone for
maximized drug loading and loading efficiency was 400 mg kafirin and 350 mg prednisolone (i.e., one
of the experimental combinations). The predicted and observed values for both prednisolone loading
and loading efficiency had an error of c. 20–30%, so the predicted value was lower than that observed
for the predicted optimal combination (Table 4). Conversely, the non-optimal combination had c. –40%
predicted error, with the predicted value being higher than the observed value for prednisolone loading
and loading efficiency. Additionally, the amount of prednisolone washed out (i.e., drug leakage) from
the optimal combination of kafirin and prednisolone that were stored at the different temperatures
was not significantly different over the six month period.
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Table 4. Predicted and observed values of the dependent responses for the optimal independent
variable combination and a ′non-optimal′ combination.
Dependent variable Predicted Value Observed Value Predicted Error (%)
Optimal independent variable combination: 400 mg kafirin and 350 mg prednisolone
Y1 = Prednisolone loading (%) 10.414 13.53 29.9
Y2 = Loading efficiency (%) 25.269 30.80 21.9
′Non-optimal′ independent variable combination: 200 mg kafirin and 200 mg prednisolone
Y1 = Prednisolone loading (%) 6.64 3.73 –43.8
Y2 = Loading efficiency (%) 13.22 8.33 –37.0
3.3. Scanning Electron Micrographs
Multiple scanning electron micrographs were taken, with two representative micrographs
presented here. Scanning electron micrographs (Figure 4a,b) confirmed the presence of round particles
that were varied in size. The surface structure of the microparticles was irregular and crinkled, though
the prednisolone loaded microparticles were generally more crenated. The prednisolone loaded
microparticles also appeared to have pores or pits on the surface.
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Figure 4. Scanning electron micrograph of microparticles formulated using 400 mg distiller’s dried
grains (DDG) kafirin (a), and 350 mg prednisolone with 400 mg DDG kafirin (b) at 50,000×.
3.4. Particle Size Distribution
The empty and prednisolone loaded microparticles formulated using DDG kafirin both had a
wide size distribution, with 90% being less than c. 34 µm (Table 5). The surface weighted mean (D(3,2))
and the volume weighted mean (D(4,3)) also indicated that the microparticles were similar in size,
regardless of whether any prednisolone was loaded.
Table 5. Particle size analysis of empty and prednisolone loaded DDG kafirin microparticles formulated
with 350 mg prednisolone, 400 mg kafirin and 0.1 M NaCl. Data shows the volume mean diameter,
d, where 10%, 50% and 90% of the particles are below the reported number, the surface area mean
diameter D(3,2) and the volume mean diameter D(4,3), all measured in µm.
Microparticles d(v,0.1) (µm) d(v,0.5) (µm) d(v,0.9) (µm) D(3,2) (µm) D(4,3) (µm)
Empty 3.317 12.535 33.519 7.632 17.205
Prednisolone loaded 2.534 8.820 34.159 5.946 15.334
3.5. In vitro Drug Release
3.5.1. Simulated Stomach and Small Intestinal Conditions
In the conditions simulating the stomach and small intestine, the extent of prednisolone release
from the commercial tablet was higher than that from the microparticles. Approximately 100% of the
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prednisolone was released from the tablets within 30 min, whereas only approximately 15–25% of
prednisolone was released from the microparticles. In both the commercial tablet and the microparticles,
the extent of drug release had peaked after 30 min, before plateauing out for the remainder of the 7 h
(Figure 5). The presence of pepsin and pancreatin did not impact upon drug release; 26.60% ± 4.37%
in the presence of enzymes versus 26.33% ± 5.93% in the absence of enzymes (mean ± SEM) (Figure 5).
Prednisolone release from both the kafirin microparticles and commercial tablets in the presence of
bile salts (Figure 6) mimicked that of the 7 h drug release study (Figure 5). Approximately 100% of the
prednisolone was released from the tablets within 30 min, while 25.67% ± 3.2% (mean ± SEM) of the
prednisolone was released from the microparticles at 1 h, before plateauing out for the remainder of
the 4 h.
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Figure 5. In vitro drug release profile of a commercially available 5 mg prednisolone tablet compared
to prednisolone release from the kafirin microparticles containing an equivalent of 5 mg prednisolone.
Prednisolone release was measured in conditions simulating the stomach for 1 h, followed by the
small intestine for 6 h, (a) without enzymes, and (b) in presence of the enzymes pepsin and pancreatin,
respectively. Values are mean ± SEM (n = 3).
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Figure 6. In vitro drug release profile of a commercially available 5 mg prednisolone tablet compared to
drug release from kafirin microparticles containing an equivalent of 5 mg prednisolone. Prednisolone
release was measured in conditions simulating the small intestine using simulated intestinal fluid,
pancreatin, and bile salt for 4 h. Values are mean ± SEM (n = 3).
3.5.2. Simulated Colonic Conditions
While 100% of the prednisolone from the tablet could be measured in the simulated gastric and
intestinal conditions, only a maximum of approximately 85% could be detected in the simulated
colonic testing when in the presence of any fecal inoculum. In previous studies, if fecal inoculum was
not included with the medium, then 100% of the prednisolone could be recovered using the 5 mg
commercial prednisolone tablet. This suggests that in this present study, 15% of the prednisolone
released could not be detected due to possible interactions with the fecal inoculum. Hence, as the
maximum amount that was detected for a tablet of 5 mg prednisolone was 4.25 mg, the prednisolone
release profile was adjusted to account for this (Figure 7).
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to drug release from kafirin microparticles containing an equivalent of 5 mg prednisolone, in conditions
simulating the colon. Medium was added to the substrates (0.5 g glucose with microparticles or tablet;
see Table 2) at –16 h, and fecal inoculum was added at 0 h. A tablet incubated in autoclaved inoculum
served as a control (Control 4 in Table 2). Values are mean ± SEM (n = 3).
Within 60 min after the medium was ad ed to the substrates (–16 h), prednisolone was detected
(Figure 7). t 0 h, i.e., the point at which the fecal inoculum was ad ed, 10 % of the prednisolone
from the tablets had be n released, while ap roximately 25% of the prednisolone had be n released
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from the microparticles. When incubated with autoclaved fecal inoculum, release from the 5 mg tablet
remained at approximately 100% for the entire 24 h incubation, but with standard fecal inoculum (i.e.,
not autoclaved) the prednisolone decreased after 4 h to approximately 65% at 12 h and 30% at 24 h.
Kafirin microparticles loaded with prednisolone responded in a similar manner to the commercial
tablet when incubated with standard fecal inoculum, in that the amount of prednisolone detected was
maximal (25%) at 0 h, but then declined from 4 h incubation to approximately 10% at 12 h. The amount
of prednisolone detected continued to decrease, such that at 19 h and 24 h there was a negligible
amount (Figure 7). No prednisolone was detected in the blank and control substrates.
4. Discussion
To be feasible as an oral drug delivery system, the amount of kafirin microparticles required to
deliver a clinically relevant dose must be thermodynamically stable and realistic for oral intake [4,23].
The RSM model described a significant linear relationship between prednisolone concentration
and prednisolone loading into the kafirin microparticles. Increasing the starting concentration of
prednisolone was associated with an increase in the amount of prednisolone retained, as was also
observed with the surface binding [23], and with previous work using zein microparticles loaded
with prednisolone [25], ivermectin [38], and gitoxin [39]. The starting concentration of kafirin was the
only significant term described in the quadratic model of loading efficiency, but only demonstrated a
trend towards significance. Higher loading efficiency was achieved with higher kafirin concentrations.
This was also consistent with prednisolone [25], ivermectin [38], and gitoxin [39] loading into zein
microparticles, tadalafil loading into microporous silica [40], and captopril loading into Eudragit® and
Methocel® microparticles [18]. This was not unexpected, as the greater availability of coating material
may have allowed more core material to become encapsulated.
However, the model also predicted that regardless of the amount of kafirin, small amounts of
prednisolone (e.g., 100 mg) would produce higher loading efficiency than larger amounts (e.g., 350 mg),
with intermediate quantities of prednisolone producing the lowest loading efficiency. This relationship
is not consistent with the trends noted for zein-prednisolone microparticles [25], nor those in the
literature [16,38,39], which suggest that larger ratios of coating material to core material produce
higher loading efficiencies. This discrepancy might be explained by the inadequacy of the generated
model. The large error noted between the predicted and observed values (Table 4) indicates the RSM
models are inadequate for accurately predicting prednisolone loading or loading efficiency. The BP
states that for prednisolone tablets, the content must be 90.0–110.0% of the stated amount [41]. As such,
the current models generated would not be acceptable tools for predicting formulations for drug
delivery purposes.
RSM is a tool that has long been used for statistical modeling. The inadequacy of the models
suggests that the data used to generate the models is lacking in robustness. During the microparticle
formulation process using 70% (v/v) ethanol, experimental variables that were controllable—such as
temperature, mixing times, intensity of vortex mixing, ethanol and NaCl concentration—were kept
constant, with only the kafirin and prednisolone quantities being varied. Of these two variables, the
quantities of prednisolone used readily dissolved in 70% ethanol at ambient temperature. However,
even at 70 ◦C, only approximately 90% of the kafirin protein could be dissolved in 70% ethanol, and
small gelled pellets of insoluble residues were formed as a result of a tendency for kafirin to gelate
when dissolved in aqueous ethanol [42]. The formation of these pellets could not be controlled during
the microparticle formulation process. Thus, inconsistencies in the amount of kafirin dissolved and
gelled pellets formed would cause unintended variability in the amount of prednisolone encapsulated,
negatively impacting upon the robustness of the model. As such, an alternate solvent such as glacial
acetic acid at 25 ◦C, which dissolved significantly more kafirin protein (c. 95%) without the formation
of gelled pellets [42], may reduce variability in the amount of prednisolone encapsulated to help
improve the robustness of the model. Additionally, the effect of NaCl on microparticles formation was
perhaps two-fold. Aside from its charge shielding effect, it may also have had an additional ′salting
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out′ effect [43] which promoted kafirin to precipitate out of solution. It is likely that prednisolone was
loaded into the kafirin microparticles when both were co-precipitated, with prednisolone and kafirin
first aggregating together into nanoparticles, then precipitating with other nanoparticle aggregations
to form the resulting microparticles. This would account for the varied sizes, and the crenated and
layered appearance of the microparticles (Figure 4). Therefore, investigating alternate methods for
formulating the microparticles may also contribute to the robustness of the model, and also formulating
microparticles that are more homogenous in size.
The initial burst release of prednisolone from the microparticles, followed by a slower sustained
release which plateaus, in simulated gastric and small intestinal conditions, is consistent with previous
work on kafirin and zein microparticles [4,25]. The lack of prednisolone released after the initial burst
release may be due to the inherent nature of the kafirin protein. The hydrophobic nature of both
the kafirin protein and prednisolone (logP = 1.62 [44]) does not favor the release of prednisolone
into an aqueous environment. This lack of further prednisolone release may be enhanced by the
hydrophobic interactions between kafirin and prednisolone. These hydrophobic interactions may also
have prevented the change in protein conformation that was observed with a pH change, resulting in
further antioxidant activity when catechins and condensed tannins were encapsulated in kafirin
microparticles [1]. The hydrophobic interactions promoted by the addition of NaCl to achieve
prednisolone loading, along with the innate low digestibility of kafirin [2,3], may have prevented
the release of prednisolone under the simulated stomach and small intestinal conditions. Digestive
enzymes and bile salts did not affect prednisolone release from the microparticles, further supporting
the postulation that the encapsulated drug is protected from the digestive processes of the upper GIT.
In simulated conditions of the colon, prednisolone was detected in the –16 h incubation time
samples. The presence of prednisolone in the medium before the addition of any fecal inoculum is
consistent with the substrates being in contact with an aqueous liquid. This was observed with the
prednisolone release in simulated conditions of the stomach and small intestine, since enzymes did
not affect the amount of prednisolone released (Figure 5). Less prednisolone was detected at –16 h
incubation time samples in the simulated colonic conditions (60 min after the medium was added to
the substrates), compared to the 1 h samples from simulated gastric conditions (Figures 5 and 7). This
may be explained by the differences in the agitation method. In the simulated gastric conditions, the
mixture was under constant agitation at 100 rpm, while the samples in the simulated colonic conditions
were gently swirled before a sample was removed. Less vigorous agitation of samples in the simulated
colonic conditions would account for the slower rate of release observed initially. Nevertheless, the
amount of prednisolone at 0 h in the simulated colonic conditions (Figure 7) is similar to the total
amount released over 7 h in simulated gastric and intestinal conditions (Figure 5). This can be likened
to the microparticles passing through the stomach and small intestine before reaching the colon (i.e.,
at 0 h).
The subsequent decrease in the amount of prednisolone quantified is consistent with the microbes
reducing the ’A ring’ of the prednisolone structure, rendering it undetectable at 254 nm [45]. This effect
of the microbes on prednisolone was also observed when prednisolone was incubated in 10% rat
cecal contents, whereby 50% of the prednisolone added was undetectable after 4 h incubation [45].
As the inoculum concentration affects the rate of prednisolone breakdown [45], this would explain
the faster decline in the 10% rat cecal contents compared to our c. 6% of porcine feces. Furthermore,
the differences in the rate of decline may also be attributed to the innate differences in the sources of
inoculum (rat cecal contents versus porcine feces), and the different diets and environments to which
these animals were exposed.
It is evident that introducing the kafirin microparticles to a reducing environment did not result
in further drug release, as the maximum amount of prednisolone was quantified at 0 h incubation time
for all substrates. It appeared that the rate of prednisolone reduction was slower with microparticles
compared to the tablet. The faster rate of prednisolone reduction with the tablet may also be explained
by the larger quantity of prednisolone in the medium when the fecal inoculum was added (5 mg
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for the tablet versus c. 1 mg for the microparticles). Additionally, the microbes incubated with the
tablets were more active, as was observed with the readings of the gas released by the microbes during
fermentation (data not shown), possibly due to the presence of fermentable excipients (maize starch
and lactose) in the tablet [46]. In contrast, kafirin appeared to inhibit the fermentation activity of the
microbes. In combination, these factors may account for the faster rate of prednisolone reduction with
the tablet. An alternate explanation for the different rates of decreasing prednisolone is that the effects
of prednisolone degradation were being counteracted by additional prednisolone release from the
microparticles. Nevertheless, the rate of prednisolone degradation was still faster than the rate of
prednisolone being released, and reduction of the ′A ring′ which causes prednisolone to be undetectable
at 254 nm also causes a decrease in the anti-inflammatory effects of prednisolone [45]. In light of this,
even if additional prednisolone was released, it is unlikely to provide any clinical benefits.
5. Conclusions
The RSM models generated were inadequate for accurately predicting the relationship between
the starting quantities of kafirin and prednisolone, and prednisolone loading and loading efficiency.
The robustness of the model needs to be improved with better data before it can be used to predict
optimal combinations to formulate kafirin microparticles loaded with prednisolone for use as an oral
drug delivery system. The lack of further prednisolone release in simulated colonic conditions suggests
that delivering prednisolone with kafirin microparticles formulated using this present method of phase
separation is unlikely to offer any clinical benefits over the currently available commercial dosage
forms. Nevertheless, the overall amount of prednisolone released from the kafirin microparticles in
conditions simulating the human digestive system demonstrates their ability to prevent the release of
entrapped core material. Further work developing the kafirin formulation and drug loading methods
may result in a delivery system that targets the lower GIT.
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